drug safety

Fierce Pharma

2nd patient dies after Sarepta's DMD gene therapy Elevidys

Sarepta has suspended giving Elevidys to non-ambulatory DMD patients in the commercial setting while it seeks FDA approval of a risk mitigation plan.

Angus Liu Jun 16, 2025 10:58am

Magnifying glass with pills on blue

FDA's CMO steps down

Apr 2, 2025 10:02am

cancelled flights

Pliant terminates lung disease trial due to adverse events

Mar 3, 2025 11:30am

Gene editing CRISPR gene therapy

Neurogene acts as gene therapy puts person in critical condition

Nov 18, 2024 8:33am

Caution sign on wet floor

Syndax stock slips after AML drug hits midstage trial goal

Nov 12, 2024 2:00pm

clock delay wait time alarm

Novartis' $2.9B MorphoSys bet stumbles as safety delays filing

Oct 29, 2024 6:16am